Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients

Pfizer

Status and phase: Completed; Phase 2

Conditions: Stress Urinary Incontinence

Treatments: Drug: Fesoterodine

Study type: Interventional

Funder types: Industry

Identifiers

NCT01042236

A0221064

Details and patient eligibility

About

The hypothesis under evaluation is that fesotorodine may provide clinical benefit in the treatment of the condition of stress urinary incontinence

Enrollment: 22 patients

Sex: Female

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female, 18 - 65 years
• SUI symptoms for longer than 3 months
• Subjects must be non-pregnant and not breastfeeding

Exclusion criteria

• Disease or medical condition affecting the bladder or urinary tract (other tan stress urinary incontinence)
• Subjects taking medication with effects on the bladder or urinary tract
• Subejcts with medical conditions which could be adversely affected by administration of fesoterodine - gastrointestinal tract disease, glaucoma, hepatic impairment

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

22 participants in 1 patient group

Arm 1

Experimental group

Treatment:

Drug: Fesoterodine